Tab. II.
Antimicrobial susceptibility of ESBL-producing P. aeruginosa isolated from hospitals of Qazvin and Tehran (n = 75).
| Antibiotics | S (%) | I (%) | R (%) |
|---|---|---|---|
| Amikacin | 44 (58.7) | 10 (13.3) | 21 (28) |
| Piperacillin-tazobactam | 40 (53.3) | 9 (12) | 26 (34.7) |
| Imipenem | 35 (46.7) | 9 (12) | 31 (41.3) |
| Meropenem | 34 (45.3) | 7 (9.3) | 34 (45.3) |
| Cefepime | 30 (40) | 1 (1.3) | 44 (58.7) |
| Piperacillin | 26 (34.7) | 8 (10.7) | 41 (54.7) |
| Ciprofloxacin | 24 (32) | 1 (1.3) | 50 (66.7) |
| Gentamicin | 22 (29.3) | - | 53 (70.7) |
| Ceftazidime | 22 (29.3) | 4 (5.3) | 49 (65.3) |
| Tobramycin | 22 (29.3) | 3 (4) | 50 (66.7) |
| Ofloxacine | 21 (28) | 2 (2.7) | 52 (69.3) |
| Levofloxacin | 18 (24) | 2 (2.7) | 55 (73.3) |
| Ticarcillin | 17 (22.7) | 1 (1.3) | 57 (76) |
| Aztreonam | 14 (18.7) | 10 (13.3) | 51 (68) |
| Carbenicilin | 14 (18.7) | 3 (4) | 58 (77.3) |
| Ceftriaxone | 10 (13.3) | 7 (9.3) | 58 (77.3) |
| Cefotaxime | 5 (6.7) | 8 (10.7) | 62 (82.7) |
S: Sensitive, I: Intermediate, R: Resistant.